IGF-1, IGFBP-3 and ALS in adult patients with chronic kidney disease

Growth Hormone and IGF Research

Volumn 20, Issue 2, 2010, Pages 93-100

  Lepenies, Julia ^a,b   Wu, Zida ^c   Stewart, Paul M ^d   Strasburger, Christian J ^c   Quinkler, Marcus ^c  

^a KfH Dialysis Center Bismarckstrasse   (Germany)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acid labile subunit; Chronic kidney disease; Creatinine clearance; IGF 1 system; Proteinuria

Indexed keywords

ACID LABILE SUBUNIT; ALBUMIN; CREATININE; PROTEIN KINASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BIOACCUMULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; FEMALE; HEMATURIA; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; COHORT STUDIES; CREATININE; FEMALE; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 77949657542     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.10.002     Document Type: Article

References (37)

1. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
2. Baxter R.C. Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J. Clin. Endocrinol. Metab. 1990, 70:1347-1353.
3. Chin E., Zhou J., Dai J., Baxter R.C., Bondy C.A. Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology 1994, 134:2498-2504.
4. Labarta J.I., Gargosky S.E., Simpson D.M., et al. Immunoblot studies of the acid-labile subunit (ALS) in biological fluids normal human serum and in children with GH deficiency and GH receptor deficiency before and after long-term therapy with GH or IGF-I respectively. Clin. Endocrinol. (Oxf) 1997, 47:657-666.
5. Ben-Shlomo A., Melmed S. Acromegaly. Endocrinol. Metab. Clin. North Am. 2008, 37:101-122. viii.
6. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society, GH Research Society, J. Clin. Endocrinol. Metab. 85 (2000) 3990-3993.
7. Vasan R.S., Sullivan L.M., D'Agostino R.B., et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham heart study. Ann. Intern. Med. 2003, 139:642-648.
8. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106:939-944.
9. Laughlin G.A., Barrett-Connor E., Criqui M.H., Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 2004, 89:114-120.
10. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
11. Goodwin P.J., Ennis M., Pritchard K.I., et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res. Treat. 2002, 74:65-76.
12. Hirschberg R., Adler S. Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications. Am. J. Kidney Dis. 1998, 31:901-919.
13. Lee D.Y., Park S.K., Kim J.S. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children with nephrotic syndrome. J. Clin. Endocrinol. Metab. 1996, 81:1856-1860.
14. Martin J.L., Baxter R.C. Insulin-like growth factor binding protein-3: biochemistry and physiology. Growth Regul. 1992, 2:88-99.
15. Dong F., Ren J. Insulin-like growth factors (IGFs) and IGF-binding proteins in nephrotic syndrome children on glucocorticoid. Pharmacol. Res. 2003, 48:319-323.
16. Frystyk J., Ivarsen P., Skjaerbaek C., Flyvbjerg A., Pedersen E.B., Orskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 1999, 56:2076-2084.
17. Bang P. Serum proteolysis of IGFBP-3. Prog. Growth Factor Res. 1995, 6:285-292.
18. Skjaerbaek C., Frystyk J., Orskov H., et al. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J. Clin. Endocrinol. Metab. 1998, 83:2445-2449.
19. Durham S.K., Mohan S., Liu F., Baker B.K., Lee P.D., Hintz R.L., Conover C.A., Powell D.R. Bioactivity of a 29-kilodalton insulin-like growth factor binding protein-3 fragment present in excess in chronic renal failure serum. Pediatr. Res. 1997, 42:335-341.
20. Collett-Solberg P.F., Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol. Metab. Clin. North Am. 1996, 25:591-614.
21. Blum W.F., Ranke M.B., Kietzmann K., Gauggel E., Zeisel H.J., Bierich J.R. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding prote: its use for diagnosis of GH deficiency. J. Clin. Endocrinol. Metab. 1990, 70:1292-1298.
22. Morrison K.M., Bidlingmaier M., Stadler S., Wu Z., Skriver L., Strasburger C.J. Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly. Eur. J. Endocrinol. 2007, 156:331-339.
23. Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann. Int. Med. 1995, 123:754-762.
24. Remuzzi G., Tognoni G. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997, 349:1857-1863.
25. Rabkin R., Schaefer F. New concepts: growth hormone, insulin-like growth factor-I and the kidney. Growth Horm. IGF Res. 2004, 14:270-276.
26. Rabkin R., Fervenza F.C., Maidment H., et al. Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failure. Kidney Int. 1996, 49:1134-1140.
27. Wuhl E., Schaefer F. Effects of growth hormone in patients with chronic renal failure: experience in children and adults. Horm. Res. 2002, 58(Suppl. 3):35-38.
28. Iglesias P., Diez J.J., Fernandez-Reyes M.J., et al. IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis. Clin. Endocrinol. (Oxf) 2004, 60:741-749.
29. Blum W.F., Ranke M.B., Kietzmann K., Tonshoff B., Mehls O. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr. Nephrol. 1991, 5:539-544.
30. Tonshoff B., Powell D.R., Zhao D., et al. Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 1997, 138:938-946.
31. Dong F., Zhou X., Pang N., Wei M. Effect of glucocorticoid treatment on insulin like growth factor-I and its binding proteins in children with nephrotic syndrome. Chin. Med. J. (Engl.) 2002, 115:1383-1385.
32. Yildiz B., Kural N., Aydin B., Colak O. Increased serum levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3 in Henoch-Schonlein purpura. Tohoku J. Exp. Med. 2008, 214:333-340.
33. Tack I., Elliot S.J., Potier M., Rivera A., Striker G.E., Striker L.J. Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes 2002, 51:182-188.
34. Oemar B.S., Foellmer H.G., Hodgdon-Anandant L., Rosenzweig S.A. Regulation of insulin-like growth factor I receptors in diabetic mesangial cells. J. Biol. Chem. 1991, 266:2369-2373.
35. Berfield A.K., Andress D.L., Abrass C.K. IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function. Kidney Int. 2002, 62:1229-1237.
36. Berfield A.K., Abrass C.K. IGF-1 induces foam cell formation in rat glomerular mesangial cells. J. Histochem. Cytochem. 2002, 50:395-403.
37. Haylor J., Hickling H., El E.E., Moir A., Oldroyd S., Hardisty C., El Nahas A.M. JB3, an IGF-I receptor antagonist, inhibits early renal growth in diabetic and uninephrectomized rats. J. Am. Soc. Nephrol. 2000, 11:2027-2035.